Radius Health to Host Conference Call Today, Wednesday, December 8, 2021
BOSTON, Dec. 08, 2021 - Radius Health announced a conference call on December 8, 2021, at 4:00 p.m. ET. The call will discuss topline results from the wearABLe Phase 3 trial and review data from the EMERALD Phase 3 trial presented at the San Antonio Breast Cancer Symposium. Interested parties can join via a domestic dial-in number at 1 (866) 323-7965 or internationally at 1 (346) 406-0961, using conference ID 7691981. A replay will be available later on the same day and archived for 90 days on the Company's website.
- None.
- None.
BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below:
- Discuss topline results from the wearABLe Phase 3 trial
- Review data presented at the San Antonio Breast Cancer Symposium from the EMERALD Phase 3 trial
Conference Call Information:
Domestic Dial-In Number: 1 (866) 323-7965
International Dial-In Number: 1 (346) 406-0961
Conference ID: 7691981
A replay of the conference call will be available on December 8 at 7:00 p.m. ET and a live audio webcast of the call will be archived on the Company's website for ninety days. To access the replay, dial (855) 859-2056 or (404) 537-3406 for International, using conference ID number 7691981. The live audio webcast of the call can be accessed from the Investors section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations.
About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide transdermal system for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases, initially targeting Prader-Willi Syndrome.
Investor & Media Relations Contact:
Ethan Holdaway
Email: investor-relations@radiuspharm.com
Phone: (617) 583-2017
FAQ
What will Radius Health discuss during the conference call on December 8, 2021?
What are the dial-in numbers for the Radius Health conference call on December 8, 2021?
What is the conference ID for Radius Health's December 8, 2021 conference call?
When will the replay of the Radius Health conference call be available?
Where can I access the live audio webcast of the Radius Health conference call?
